Fisher Wallace Laboratories

Last updated

Fisher Wallace Laboratories, Inc., headquartered in New York City, markets the Fisher Wallace Stimulator, a cranial electrotherapy stimulation (CES) device. [1] [2] The company was founded in 2007 by entrepreneur Charles Avery Fisher, son of electronics pioneer Avery Fisher, and Martin Wallace. [3] [4] The company acquired its lead product from Saul and Bernard Liss in 2006. [4] Inc. magazine rated the company as being #983 (in 2014) and #1447 (in 2015) in its "Inc. 5000" listing. [5] [6] The Lisses had already obtained 510K marketing clearance from the Food and Drug Administration to treat anxiety, depression, and insomnia when Fisher-Wallace acquired it. [7]

Fisher-Wallace renamed the device as the FW-100 Cranial Stimulator Device, and it was approved for marketing by Health Canada in 2014 under Licence No. 92984; in 2015 Health Canada received a complaint about Fisher Wallace's marketing on its website and sent an enforcement letter concerning the false marketing, which the company corrected. [8] A 2014 Cochrane review found insufficient evidence to determine whether CES devices with alternating current are safe and effective for treating depression. [9]

Fisher-Wallace is a late entry to the CES field; such devices have been marketed since the 1940s, especially in Russia. [3] It has heavily marketed its device via YouTube [3] and other media [10] with pitches that, according to Jessa Gamble writing in Aeon , have "all the trappings of a late-night infomercial". [4]

Fisher was credited by Neurotech Reports editor and publisher James Cavuoto with playing a leading role in the FDA's 2014 withdrawal of its earlier proposal to require companies marketing CES devices to conduct new clinical trials to prove the safety and efficacy of the devices and to submit Premarket Approval applications in order to continue marketing the devices; [11] the company had alleged that the FDA improperly barred an expert in the field from attending a 2014 advisory meeting to discuss the proposed regulation. [12] In 2016, in response to the FDA's next effort to regulate the device class, the company alleged that there was "evidence of regulatory misconduct" and called for an investigation. [13]

Related Research Articles

<span class="mw-page-title-main">Transcranial magnetic stimulation</span> Brain stimulation using magnetic fields

Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to induce an electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil connected to the scalp. The stimulator generates a changing electric current within the coil which creates a varying magnetic field, inducing a current within a region in the brain itself.

<span class="mw-page-title-main">Trifluoperazine</span> Typical antipsychotic medication

Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia. It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines. It is of the phenothiazine chemical class. It was approved for medical use in the United States in 1959.

<span class="mw-page-title-main">Quetiapine</span> Atypical antipsychotic medication

Quetiapine, sold under the brand name Seroquel among others, is an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Despite being widely used as a sleep aid, the benefits of such use may not outweigh the risk of undesirable side effects. It is taken orally.

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

<span class="mw-page-title-main">Cranial electrotherapy stimulation</span> Form of neurostimulation

Cranial electrotherapy stimulation (CES) is a form of neurostimulation that delivers a small, pulsed, alternating current via electrodes on the head. CES is used with the intention of treating a variety of conditions such as anxiety, depression and insomnia. CES has been suggested as a possible treatment for headaches, fibromyalgia, smoking cessation, and opiate withdrawal, but there is little evidence of effectiveness for many of these conditions and the evidence for use in acute depression is not sufficient to justify it.

<span class="mw-page-title-main">Transcutaneous electrical nerve stimulation</span> Therapeutic technique

A transcutaneous electrical nerve stimulation is a device that produces mild electric current to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation, but the term is often used with a more restrictive intent, namely, to describe the kind of pulses produced by portable stimulators used to reduce pain. The unit is usually connected to the skin using two or more electrodes which are typically conductive gel pads. A typical battery-operated TENS unit is able to modulate pulse width, frequency, and intensity. Generally, TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction or low frequency (<10 Hz) with an intensity that produces motor contraction. More recently, many TENS units use a mixed frequency mode which alleviates tolerance to repeated use. Intensity of stimulation should be strong but comfortable with greater intensities, regardless of frequency, producing the greatest analgesia. While the use of TENS has proved effective in clinical studies, there is controversy over which conditions the device should be used to treat.

<span class="mw-page-title-main">Violet ray</span> Antique medical appliance

A violet ray is an antique medical appliance used during the early 20th century to discharge in electrotherapy. Their construction usually featured a disruptive discharge coil with an interrupter to apply a high voltage, high frequency, low current to the human body for therapeutic purposes.

<span class="mw-page-title-main">Electrotherapy</span> Use of electricity for medical purposes, and to stimulate Muscle for more strength.

Electrotherapy is the use of electrical energy as a medical treatment. In medicine, the term electrotherapy can apply to a variety of treatments, including the use of electrical devices such as deep brain stimulators for neurological disease. The term has also been applied specifically to the use of electric current to speed wound healing. The use of EMS is also very wide for managing muscular pain. Additionally, the term "electrotherapy" or "electromagnetic therapy" has also been applied to a range of alternative medical devices and treatments. Evidence supporting the effectiveness of electrotherapy is limited.

<span class="mw-page-title-main">Eszopiclone</span> Hypnotic medication

Eszopiclone, sold under the brand name Lunesta among others, is a medication used in the treatment of insomnia. Evidence supports slight to moderate benefit up to six months. It is taken by mouth.

<span class="mw-page-title-main">Vagus nerve stimulation</span> Medical treatment that involves delivering electrical impulses to the vagus nerve

Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy, cluster headaches, treatment-resistant depression and stroke rehabilitation.

<span class="mw-page-title-main">Transcranial direct-current stimulation</span> Technique of brain electric stimulation therapy

Transcranial direct current stimulation (tDCS) is a form of neuromodulation that uses constant, low direct current delivered via electrodes on the head. It was originally developed to help patients with brain injuries or neuropsychiatric conditions such as major depressive disorder. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way, as well as transcranial magnetic stimulation.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. 

<span class="mw-page-title-main">Responsive neurostimulation device</span> Category of medical devices that respond to signals in a patients body to treat disease

Responsive neurostimulation device is a medical device that senses changes in a person's body and uses neurostimulation to respond in the treatment of disease. The FDA has approved devices for use in the United States in the treatment of epileptic seizures and chronic pain conditions. Devices are being studied for use in the treatment of essential tremor, Parkinson's disease, Tourette's syndrome, depression, obesity, and post-traumatic stress disorder.

Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.

<span class="mw-page-title-main">Pulsed electromagnetic field therapy</span> Attempted medical therapy using electromagnetic fields

Pulsed electromagnetic field therapy, also known as low field magnetic stimulation (LFMS) is the use of electromagnetic fields in an attempt to heal non-union fractures and depression. By 2007 the FDA had cleared several such stimulation devices.

<span class="mw-page-title-main">Brainsway</span>

BrainsWay Ltd. is an international company that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a non-invasive treatment for depression, OCD, and smoking addiction. The company was founded in 2003 and has offices in the US and Jerusalem.

Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli such as a magnetic field (rTMS), an electric current, or a drug instilled directly in the subdural space. Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation.

<span class="mw-page-title-main">Zynex</span> Medical device manufacturer

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996.

<span class="mw-page-title-main">Abraham Zangen</span> Israeli researcher

Abraham Zangen is an Israeli professor of neuroscience, head of the brain stimulation and behavior lab and chair of the psychobiology brain program at Ben-Gurion University of the Negev (BGU).

References

  1. ↑ Allison Shelley for Medscape News. February 17, 2012 Electrical Stimulators Need High-Risk Rating, Says FDA Panel
  2. ↑ Staff, Sleep Review. June 11, 2014 FDA To Propose Approval/Reclassification of Cranial Electrotherapy Stimulation Devices for Insomnia
  3. 1 2 3 Melinda Beck for the Wall Street Journal. Jan. 11, 2011 "Using Electricity, Magnets for Mental Illness"
  4. 1 2 3 Jessa Gamble, New technologies are emerging that could radically reduce our need to sleep – if we can bear to use them, Aeon Magazine
  5. ↑ "Fisher Wallace Laboratories". Inc. 2016. (In archive link, click on list that leads to #1447.)
  6. ↑ Dagdeviren, Canan (December 1, 2017). "Event: Biotech Wearables for the Treatment of Mental Health Symptoms". MIT Media Lab. Retrieved 30 March 2018.
  7. ↑ Mindes, Janet; Dubin, Mark J.; Altemus, Margaret (November 15, 2014). "Chapter 11 Cranial Electric Stimulation". In Knotkova, Helena; Rasche, Dirk (eds.). Textbook of Neuromodulation: Principles, Methods and Clinical Applications (2015 ed.). Springer. p. 129. ISBN   978-1493914074. Subsection: "Contemporary Devices and Clinical Applications".
  8. ↑ "Health Product Advertising Complaints". Health Canada. 26 March 2015. Retrieved 28 September 2017.
  9. ↑ Kavirajan HC, Lueck K, Chuang K (2014). "Alternating current cranial electrotherapy stimulation (CES) for depression". Cochrane Database Syst Rev. 7 (7): CD010521. doi: 10.1002/14651858.CD010521.pub2 . PMC   10554095 . PMID   25000907. Rigorous clinical trial evidence is lacking on the use of cranial electrotherapy stimulation (CES) in acute depression. Thus, at present, there is insufficient evidence on which to base decisions for using CES in treatment of acute depression
  10. ↑ John Horgan for Scientific American. June 24, 2015 Return of Electro-Cures: Symptom of Psychiatry's Crisis?
  11. ↑ James Cavuoto, Neurotech Reports. June 2014 Editorial: Using Our Cranium
  12. ↑ Mark McCarty for Medical Device Daily April 9, 2012 Fisher Wallace hints at FDA misconduct at CES advisory
  13. ↑ Marie Thibault for MDDI. April 20, 2016 Patients, Clinicians Advocate for Cranial Electrotherapy Stimulators
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.